Phase IIb Trial Will Further Assess Efficacy, Safety And Tolerability Of MK-7009 - For Patients With Chronic Hepatitis C

Results from an ongoing Phase IIa study showed that MK-7009, Merck Sharp and Dohme’s (MSD) investigational oral hepatitis C virus (HCV) protease inhibitor, in combination therapy significantly improved rapid viral response, defined as viral suppression to undetectable levels within 28 days, compared to placebo in combination therapy in previously untreated (treatment-naïve) patients infected with chronic HCV genotype 1, one of the most difficult to treat genotypes of HCV (p

More: continued here

Filed under: Clinical Trials on May 12th, 2009